Reference is to Printer's Date 2/15/17-H.
Amend the bill, as and if amended, Section 40-43-86(H)(7) and (8), as contained in SECTION 5, page 14, by striking the items in their entirety and inserting:
/ (7)
Within seven business days following the
dispensing of a biological product, the dispensing pharmacist or
the pharmacist's designee shall make an entry of the specific
biological product provided to the patient, including the name
of the biological product and the manufacturer. The
communication must be conveyed by making an entry that is
electronically accessible to the prescriber through: (i) an
interoperable electronic medical records system; (ii) an
electronic prescribing technology; (iii) a pharmacy benefit
management system; or (iv) a pharmacy record. Entry into an
electronic records system as described in this section is
presumed to provide notice to the prescriber. Otherwise, the
pharmacist shall communicate the biological product dispensed to
the prescriber using facsimile, telephone, electronic
transmission, or other prevailing means, provided that
communication is not required when:
(a)
there is no federal Food and Drug Administration
approved interchangeable biological product for the product
prescribed; or
(b)
a refill prescription is not changed from the
product dispensed on the prior filling of the prescription;
or
(c) a
biological product is dispensed for inpatient hospital services
or is a hospital-administered biological product for
outpatients.
The communication by the dispensing
pharmacist or the pharmacist's designee must be monitored by the
pharmacist in charge." /
Renumber sections to conform.
Amend title to conform.